{"id":36296,"date":"2015-05-28T06:06:42","date_gmt":"2015-05-28T10:06:42","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=36296"},"modified":"2015-05-28T06:06:42","modified_gmt":"2015-05-28T10:06:42","slug":"abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296","title":{"rendered":"Abbvie Inc (NYSE:ABBV) Quickens Stake Buybacks Following Pharmacyclics, Inc. (NASDAQ:PCYC) Deal"},"content":{"rendered":"<p style=\"text-align: justify;\">On Wednesday, <strong>AbbVie Inc (NYSE:ABBV)<\/strong> announced that it would reacquire shares after the acquisition of <strong>Pharmacyclics, Inc. (NASDAQ:PCYC) <\/strong>was finalized.<\/p>\n<p style=\"text-align: justify;\">The company announced its plans to buy back stock worth $5 billion from Morgan Stanley. The announcement was made as soon as the acquisition was completed. The news that AbbVie had plans to acquire Pharmacyclics first hit the airwaves two months ago towards the end of the first quarter.<\/p>\n<p style=\"text-align: justify;\">The two companies finalized the deal making process on Tuesday. News of the buyout revealed that the acquisition was worth $21 billion according to the agreement by both firms. AbbVie announced that it would speed up a program to re-acquire part of the equity used to facilitate the transaction once the deal making is complete.<\/p>\n<p style=\"text-align: justify;\">In March, the company raised its share buy-back endorsement from $5 billion to $10 billion. Morgan Stanley is supposed to deliver the first batch of shares on Wednesday. The batch will contain 68 million shares.<\/p>\n<p style=\"text-align: justify;\">AbbVie sold new bonds worth $16.7 billion at the start of May to leverage capital for the Acquisition of Pharmacyclics. The hefty amount places AbbVie bonds as one of the corporate bond contracts in 2015.<\/p>\n<p style=\"text-align: justify;\">The share buyback is expected to come to a completion in a few years. This will allow the company enough time to recover funds. It is also strategic as a means to make sure that the company\u2019s balance sheet is not dented. What this means is that the firm will be able to disperse the costs over multiple periods, making it easier to recover.<\/p>\n<p style=\"text-align: justify;\">The buybacks will be made with Board discretion. This is because the authorization allows the stock to be bought back through private transactions. Despite the fact that they have no limit, they may be halted at any time. Abbvie Inc (NYSE:ABBV) has a long history as a research Biopharmaceutical Firm. The company has always employed distinctive innovation tactics for the development of advanced therapies to handle some of the most abrasive conditions.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On Wednesday, AbbVie Inc (NYSE:ABBV) announced that it would reacquire shares after the acquisition of Pharmacyclics, Inc. (NASDAQ:PCYC) was finalized. The company announced its plans [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":21657,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1593,1743,1592,5774],"stock_ticker":[],"class_list":["post-36296","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-abbvie-inc-nyseabbv","tag-nasdaqpcyc","tag-nyseabbv","tag-pharmacyclics-inc-nasdaqpcyc","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Abbvie Inc (NYSE:ABBV) Quickens Stake Buybacks Following Pharmacyclics, Inc. (NASDAQ:PCYC) Deal - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abbvie Inc (NYSE:ABBV) Quickens Stake Buybacks Following Pharmacyclics, Inc. (NASDAQ:PCYC) Deal - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"On Wednesday, AbbVie Inc (NYSE:ABBV) announced that it would reacquire shares after the acquisition of Pharmacyclics, Inc. (NASDAQ:PCYC) was finalized. The company announced its plans [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-05-28T10:06:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"456\" \/>\n\t<meta property=\"og:image:height\" content=\"190\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Abbvie Inc (NYSE:ABBV) Quickens Stake Buybacks Following Pharmacyclics, Inc. (NASDAQ:PCYC) Deal\",\"datePublished\":\"2015-05-28T10:06:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296\"},\"wordCount\":340,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\",\"keywords\":[\"AbbVie Inc. (NYSE:ABBV)\",\"NASDAQ:PCYC\",\"NYSE:ABBV\",\"Pharmacyclics Inc. (NASDAQ:PCYC)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296\",\"name\":\"Abbvie Inc (NYSE:ABBV) Quickens Stake Buybacks Following Pharmacyclics, Inc. (NASDAQ:PCYC) Deal - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\",\"datePublished\":\"2015-05-28T10:06:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\",\"width\":456,\"height\":190},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abbvie Inc (NYSE:ABBV) Quickens Stake Buybacks Following Pharmacyclics, Inc. (NASDAQ:PCYC) Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abbvie Inc (NYSE:ABBV) Quickens Stake Buybacks Following Pharmacyclics, Inc. (NASDAQ:PCYC) Deal - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296","og_locale":"en_US","og_type":"article","og_title":"Abbvie Inc (NYSE:ABBV) Quickens Stake Buybacks Following Pharmacyclics, Inc. (NASDAQ:PCYC) Deal - Wall Street PR","og_description":"On Wednesday, AbbVie Inc (NYSE:ABBV) announced that it would reacquire shares after the acquisition of Pharmacyclics, Inc. (NASDAQ:PCYC) was finalized. The company announced its plans [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-05-28T10:06:42+00:00","og_image":[{"width":456,"height":190,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Abbvie Inc (NYSE:ABBV) Quickens Stake Buybacks Following Pharmacyclics, Inc. (NASDAQ:PCYC) Deal","datePublished":"2015-05-28T10:06:42+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296"},"wordCount":340,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","keywords":["AbbVie Inc. (NYSE:ABBV)","NASDAQ:PCYC","NYSE:ABBV","Pharmacyclics Inc. (NASDAQ:PCYC)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296","url":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296","name":"Abbvie Inc (NYSE:ABBV) Quickens Stake Buybacks Following Pharmacyclics, Inc. (NASDAQ:PCYC) Deal - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","datePublished":"2015-05-28T10:06:42+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","width":456,"height":190},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbv-quickens-stake-buybacks-following-pharmacyclics-inc-nasdaqpcyc-deal-36296#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Abbvie Inc (NYSE:ABBV) Quickens Stake Buybacks Following Pharmacyclics, Inc. (NASDAQ:PCYC) Deal"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/36296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=36296"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/36296\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/21657"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=36296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=36296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=36296"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=36296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}